PDUFA VII Negotiations Completed, Commitment Letter Ratification Ongoing
Executive Summary
The US FDA, HHS and White House, as well as industry groups, now must sign off on the document.
You may also be interested in...
PDUFA VII Could Increase Transparency Of REMS Release Process
Proposed commitment letter language included a look at eliminating REMS, potentially to more clearly outline the process.
The COVID Boom: CBER Receives More INDs in One Quarter Than The Previous 30 Combined
Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.
PDUFA VII: FDA, Industry Agree To Set Minimum Carryover Balance Levels
The minimum total will increase from eight weeks of operating expenses in FY 2023 to 10 weeks by FY 2025.